Orbit Genomics is a precision healthcare company built around the patented, AI-enabled OrbiSeq™ platform, enabling clinically actionable products spanning diagnosis, treatment, prevention, and healthy aging. Unlike conventional genomics, which primarily analyzes genes and single nucleotide polymorphisms (SNPs), OrbiSeq unlocks a previously inaccessible layer of genomic biology through genome-wide analysis of short tandem repeats (STRs). By combining STRs with SNPs, OrbiSeq captures both inherited risk and active disease biology, providing insights unavailable through conventional genomics.

Our lead product, OrbiSeq-L™, is the first blood test to achieve diagnostic-level accuracy in patients with indeterminate pulmonary nodules (IPNs), enabling the non-invasive diagnosis of early-stage lung cancer. OrbiSeq-L addresses a significant unmet clinical need while validating the broader capabilities of the OrbiSeq platform.

While lung cancer is our commercial beachhead, OrbiSeq is a scalable precision healthcare platform with demonstrated applications across multiple diseases and therapeutic areas. Leveraging a single underlying genomics platform, Orbit Genomics is developing a pipeline of clinically actionable products extending well beyond oncology.